Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 - Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer's disease - Presentations include an assessment of the correlation between reductions in amyloid beta and other biomarkers of Alzheimer's disease and clinical decline after treatment with ADUHELM - Presentation on ARIA data from Phase 3 trials provides insights for effective monitoring and management in real-world clini...
Source: jcnnewswire.com